| Revision as of 00:27, 8 December 2019 editRax (talk | contribs)IP block exemptions423 edits →top: üpdated entry for ChemSpiderID← Previous edit | Latest revision as of 07:20, 3 July 2023 edit undoCitation bot (talk | contribs)Bots5,393,691 edits Add: bibcode. | Use this bot. Report bugs. | Suggested by Spinixster | Category:Glucosides | #UCB_Category 7/60 | ||
| Line 46: | Line 46: | ||
| When comparing a normal strain of ''S. aureus'' with a strain modified to lack staphyloxanthin, the wildtype pigmented strain was more likely to survive incubation with an oxidizing chemical such as ] than the mutant strain was. Colonies of the two strains were also exposed to human ]. The mutant colonies quickly succumbed while many of the pigmented colonies survived. Wounds on mice were inoculated with the two strains. The pigmented strains created lingering ]es. Wounds with the unpigmented strains healed quickly. These tests suggest that the staphyloxanthin may be key to the ability of ''S. aureus'' to survive immune system attacks. | When comparing a normal strain of ''S. aureus'' with a strain modified to lack staphyloxanthin, the wildtype pigmented strain was more likely to survive incubation with an oxidizing chemical such as ] than the mutant strain was. Colonies of the two strains were also exposed to human ]. The mutant colonies quickly succumbed while many of the pigmented colonies survived. Wounds on mice were inoculated with the two strains. The pigmented strains created lingering ]es. Wounds with the unpigmented strains healed quickly. These tests suggest that the staphyloxanthin may be key to the ability of ''S. aureus'' to survive immune system attacks. | ||
| Drugs designed to inhibit the bacterium's production of the staphyloxanthin may weaken it and renew its susceptibility to antibiotics.<ref name="JExpMed2005-Liu">{{cite journal |vauthors=Liu GY, Essex A, Buchanan JT, Datta V, Hoffman HM, Bastian JF, Fierer J, Nizet V | title=Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity | journal=J Exp Med | year=2005 | pages=209–15 | volume=202 | issue=2 | pmid=16009720 | doi=10.1084/jem.20050846 | pmc=2213009}}</ref> In fact, because of similarities in the pathways for biosynthesis of staphyloxanthin and human ], a drug developed in the context of cholesterol-lowering therapy was shown to block ''S. aureus'' pigmentation and disease progression in a ].<ref name="Science2008-Liu">{{cite journal |vauthors=Liu CI, Liu GY, Song Y, Yin F, Hensler ME, Jeng WY, Nizet V, Wang AH, Oldfield E | title=A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence | journal=Science | year=2008 | pages=391–94 | volume=319| pmid=18276850 | doi=10.1126/science.1153018 | issue=5868 | pmc=2747771}}</ref> | Drugs designed to inhibit the bacterium's production of the staphyloxanthin may weaken it and renew its susceptibility to antibiotics.<ref name="JExpMed2005-Liu">{{cite journal |vauthors=Liu GY, Essex A, Buchanan JT, Datta V, Hoffman HM, Bastian JF, Fierer J, Nizet V | title=Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity | journal=J Exp Med | year=2005 | pages=209–15 | volume=202 | issue=2 | pmid=16009720 | doi=10.1084/jem.20050846 | pmc=2213009}}</ref> In fact, because of similarities in the pathways for biosynthesis of staphyloxanthin and human ], a drug developed in the context of cholesterol-lowering therapy was shown to block ''S. aureus'' pigmentation and disease progression in a ].<ref name="Science2008-Liu">{{cite journal |vauthors=Liu CI, Liu GY, Song Y, Yin F, Hensler ME, Jeng WY, Nizet V, Wang AH, Oldfield E | title=A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence | journal=Science | year=2008 | pages=391–94 | volume=319| pmid=18276850 | doi=10.1126/science.1153018 | issue=5868 | pmc=2747771| bibcode=2008Sci...319.1391L }}</ref> | ||
| ==References== | ==References== | ||
Latest revision as of 07:20, 3 July 2023
| |
| Names | |
|---|---|
| IUPAC name [(2S,3R,4S,5S,6R)-3,4, 5-Trihydroxy-6-oxymethyl]oxan-2-yl] (2E,4E,6E,8E,10E,12E,14E,16E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,22-decaenoate | |
| Identifiers | |
| CAS Number | |
| 3D model (JSmol) | |
| ChEBI | |
| ChemSpider | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
InChI
| |
SMILES
| |
| Properties | |
| Chemical formula | C51H78O8 |
| Molar mass | 819.177 g·mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
 N verify (what is ?)
Infobox references
| |
Staphyloxanthin is a carotenoid pigment that is produced by some strains of Staphylococcus aureus, and is responsible for the characteristic golden color that gives S. aureus its species name. Staphyloxanthin also acts as a virulence factor. It has an antioxidant action that helps the microbe evade death by reactive oxygen species produced by the host immune system.
When comparing a normal strain of S. aureus with a strain modified to lack staphyloxanthin, the wildtype pigmented strain was more likely to survive incubation with an oxidizing chemical such as hydrogen peroxide than the mutant strain was. Colonies of the two strains were also exposed to human neutrophils. The mutant colonies quickly succumbed while many of the pigmented colonies survived. Wounds on mice were inoculated with the two strains. The pigmented strains created lingering abscesses. Wounds with the unpigmented strains healed quickly. These tests suggest that the staphyloxanthin may be key to the ability of S. aureus to survive immune system attacks.
Drugs designed to inhibit the bacterium's production of the staphyloxanthin may weaken it and renew its susceptibility to antibiotics. In fact, because of similarities in the pathways for biosynthesis of staphyloxanthin and human cholesterol, a drug developed in the context of cholesterol-lowering therapy was shown to block S. aureus pigmentation and disease progression in a mouse infection model.
References
- Clauditz A, Resch A, Wieland KP, Peschel A, Götz F (August 2006). "Staphyloxanthin plays a role in the fitness of Staphylococcus aureus and its ability to cope with oxidative stress". Infection and Immunity. 74 (8): 4950–3. doi:10.1128/IAI.00204-06. PMC 1539600. PMID 16861688.
- Liu GY, Essex A, Buchanan JT, Datta V, Hoffman HM, Bastian JF, Fierer J, Nizet V (2005). "Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity". J Exp Med. 202 (2): 209–15. doi:10.1084/jem.20050846. PMC 2213009. PMID 16009720.
- Liu CI, Liu GY, Song Y, Yin F, Hensler ME, Jeng WY, Nizet V, Wang AH, Oldfield E (2008). "A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence". Science. 319 (5868): 391–94. Bibcode:2008Sci...319.1391L. doi:10.1126/science.1153018. PMC 2747771. PMID 18276850.